Management of Mixed Connective Tissue Disease (MCTD)

Initial Diagnostic Assessment

• High‑resolution chest CT and pulmonary function testing with DLCO should be performed to screen for interstitial lung disease, which occurs in 40–80 % of MCTD patients and is a leading cause of mortality【1】【2】.
• Baseline laboratory evaluation—including inflammatory markers, complete blood count, comprehensive metabolic panel, and creatine kinase—should be obtained to assess organ involvement【3】.

First‑Line Pharmacologic Therapy

• Mycophenolate is conditionally recommended as the preferred first‑line immunosuppressive agent for all organ manifestations of MCTD, with the strongest evidence for preventing and treating interstitial lung disease【4】.
• Azathioprine is a conditional alternative for patients who cannot tolerate mycophenolate【4】.
• Rituximab is conditionally recommended across all systemic autoimmune‑related interstitial lung disease subtypes, including MCTD【4】.
• Glucocorticoids should be used cautiously and limited to the lowest effective dose (< 15 mg prednisone‑equivalent daily) in patients with a systemic‑sclerosis phenotype because higher doses markedly increase the risk of scleroderma renal crisis【4】.
  
  • Short‑term courses (≤ 3 months) are permissible for acute disease flares【4】.
  • Long‑term high‑dose glucocorticoid monotherapy should be avoided【4】.

Organ‑Specific Management

Raynaud Phenomenon

• Implement practical cold‑avoidance measures (e.g., insulated gloves, heated environments, thorough skin drying)【5】.
• Add pharmacologic vasodilators when severity warrants【5】.

Myositis / Myalgias

• In the presence of markedly elevated creatine kinase or muscle weakness, initiate pulse intravenous methylprednisolone followed by oral glucocorticoids combined with mycophenolate or methotrexate【3】.

Monitoring and Surveillance

• Perform pulmonary function tests every 6 months for the first 3–4 years, especially in patients with a systemic‑sclerosis phenotype【1】.
• Obtain annual high‑resolution chest CT during the first 3–4 years after diagnosis【1】.

Treatment Escalation for Progressive Disease

• If interstitial lung disease progresses despite mycophenolate, rituximab is conditionally recommended【4】.
• Cyclophosphamide is advised for severe or rapidly progressive manifestations【4】.
• Intravenous immunoglobulin (IVIG) may be added for progressive MCTD‑ILD【4】.
• Nintedanib can be considered for progressive fibrosing ILD【4】.
• Calcineurin inhibitors (tacrolimus or cyclosporine) are alternative options【4】.

Rapidly Progressive ILD Protocol

• Define rapid progression as a ≥ 10 % decline in forced vital capacity within 6 months or acute respiratory deterioration.
• Administer pulse intravenous methylprednisolone (500–1000 mg daily for 3 days)【4】.
• Prefer combination immunosuppression (double or triple therapy) over monotherapy【4】.
• Consider an upfront regimen of rituximab + cyclophosphamide + glucocorticoids【4】.
• Refer early for lung‑transplantation evaluation【4】.

Critical Pitfalls

• Do not delay ILD screening; up to 50 % of MCTD‑ILD patients experience disease progression even when asymptomatic【2】.
• Avoid high‑dose glucocorticoids (> 15 mg prednisone daily) in patients with systemic‑sclerosis features due to the heightened risk of renal crisis【4】.
• Do not rely solely on symptoms (e.g., dyspnea) to monitor ILD, as functional decline may be silent【2】.

Multidisciplinary Care

• Coordinate care among rheumatology (lead), pulmonology, and cardiology to address ILD risk and pulmonary‑hypertension screening【2】.
• Pulmonology should co‑manage ILD with serial monitoring and initiate antifibrotic therapy when indicated【2】【4】.

Treatment Approach for Mixed Connective Tissue Disease

First-Line Treatment Options

• The American College of Rheumatology recommends mycophenolate as the preferred first-line therapy for MCTD, particularly when interstitial lung disease (ILD) is present, with a strength of evidence based on clinical guidelines 6, 7
• Azathioprine is a conditionally recommended alternative first-line option for MCTD-ILD, according to clinical guidelines 6, 7
• Tocilizumab may be considered as a first-line option, especially for patients with features resembling systemic sclerosis, based on clinical evidence 6, 7
• Rituximab is conditionally recommended across all systemic autoimmune rheumatic disease-associated ILD subtypes, including MCTD, with a moderate strength of evidence 6

Organ-Specific Treatment Approaches

For MCTD with Interstitial Lung Disease

• All patients diagnosed with MCTD should undergo screening with high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) at diagnosis, as recommended by clinical guidelines 7
• Follow-up should include PFTs every 6 months and annual HRCT for the first 3-4 years after diagnosis, especially in patients with systemic sclerosis phenotype, based on clinical evidence 7
• Mycophenolate is the preferred first-line therapy for MCTD-ILD, with a high strength of evidence 6, 7
• For progressive MCTD-ILD, options include rituximab, cyclophosphamide, and nintedanib, according to clinical guidelines 6
• For rapidly progressive ILD, pulse intravenous methylprednisolone, rituximab, cyclophosphamide, IVIG, or combination therapy may be needed, based on clinical evidence 6

Treatment Based on Disease Severity

Moderate to Severe Disease

• Immunosuppressive therapy with mycophenolate, azathioprine, or methotrexate based on organ involvement is recommended, with a moderate strength of evidence 6
• For severe or life-threatening manifestations (e.g., rapidly progressive ILD, pulmonary arterial hypertension), more aggressive therapy with cyclophosphamide or rituximab may be required, based on clinical guidelines 6

Monitoring and Follow-up

• Regular assessment of disease activity and organ involvement is crucial, as recommended by clinical guidelines 7
• For patients with ILD, regular pulmonary function tests and imaging are necessary, with a high strength of evidence 7
• A multidisciplinary approach involving rheumatologists, pulmonologists, and other specialists as needed is recommended, based on clinical evidence 8, 9

Important Considerations and Pitfalls

• Glucocorticoids should be used cautiously in patients with features of systemic sclerosis due to increased risk of scleroderma renal crisis, with a high strength of evidence 6, 7
• Early recognition and treatment of ILD is crucial as it can progress to irreversible fibrosis, based on clinical guidelines 6
• Treatment decisions should consider the specific organ involvement, disease severity, and progression rate, with a moderate strength of evidence 6
• Regular screening for complications such as pulmonary arterial hypertension is essential, as recommended by clinical guidelines 7